Johnson & Johnson (NYSE:JNJ) Faces a Potential Downside According to Barclays Despite Pharmaceutical Advancements

Group 1 - Johnson & Johnson (JNJ) is a global healthcare company with a market capitalization of approximately $494.72 billion, known for its pharmaceuticals, medical devices, and consumer health products [5][6] - Barclays has set a price target of $197 for JNJ, indicating a potential downside of about -4.06% from the current trading price of $205.34 [1][6] - The stock has shown significant volatility, with a 52-week high of $207.81 and a low of $140.68, reflecting fluctuations in market performance [4][5] Group 2 - The European Commission has approved IMAAVY® (nipocalimab) for treating generalized myasthenia gravis (gMG), marking a significant advancement in JNJ's pharmaceutical division [2][6] - Nipocalimab demonstrated a rapid and substantial reduction in immunoglobulin G levels in pivotal studies, providing up to 20 months of sustained disease control and symptom relief for patients [3]